Biotech News
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
investors.larimartx.com2026-05-06 15:04 EST
In the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriers Consistent directional improvement across mFARS, FARS-ADL, 9-HPT and MFIS after 1-year in OL study reinforces the potential of